Company: ARMP
Filing Date: 2025-12-01
Form Type: 8-K
Source: 0001104659-25-117387
Chunk: 0

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

On December 1, 2025, Armata
Pharmaceuticals, Inc. (the “ Company”) entered into a Capital on Demand™ Sales Agreement (the “ Sales
Agreement”) with JonesTrading Institutional Services LLC (“ Jones”) with respect to an at the market offering
program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value
$0.01 per share (the “ Common Stock”), having an aggregate offering price of up to $100,000,000 (the “ Placement
Shares”) subject to certain conditions, through Jones as sales agent. The issuance and sale, if any, of the Placement Shares
by the Company under the Sales Agreement will be made pursuant to the Company’s effective registration statement on
Form S-3 (File No. 333-289585) (the “ Registration Statement”) and the prospectus supplement dated December 1,
2025, and filed with the U. S. Securities and Exchange Commission (the “ SEC”) pursuant to Rule 424(b) under the
Securities Act of 1933, as amended (the “ Securities Act”).

Jones may sell the Placement Shares by any method permitted by law
deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act, including, without
limitation, sales made on or through the NYSE American (“ NYSE American”) or any other existing trading market for the Common
Stock. Subject to the terms of a placement notice, Jones may also sell Placement Shares by any other method permitted by law, including
but not limited to in negotiated transactions, subject to the prior written consent of the Company.

Jones will use commercially reasonable efforts consistent with its
normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the NYSE American,
to sell the Placement Shares from time to time, up to the amount specified in, and otherwise in accordance with the terms of the applicable
placement notice. The Company will pay Jones a commission of up to 3.0% of the gross sales proceeds of any Placement Shares sold through
Jones under the Sales Agreement. In addition, the Company has agreed to reimburse certain legal expenses by Jones in connection with the
offering.

The Company is not obligated to sell, and Jones is not obligated to
buy or sell, any